Anti-Human CD80 (Galiximab Biosimilar)
Catalog #500030
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500030 | 1 mg | $250.00 | ||
| 500030 | 5 mg | $750.00 | ||
| 500030 | 20 mg | $2,000.00 |
Product Details
Galiximab is a humanized monoclonal antibody targeting CD80 (Cluster of Differentiation 80), which plays a critical role in immune response modulation. CD80 is involved in activating T-cells by binding to the CD28 receptor, making it a key target in autoimmune diseases and cancer therapies. The biosimilar of Galiximab, derived from recombinant human IgG1, has been used in research settings for applications like neutralization assays, ELISA, and bioanalytical studies of its therapeutic potential.
Specifications
| Clone | Galiximab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 6.0 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human CD80 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |